- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07943728
Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention (YARD-01)
A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Yangyin Qingfei Decoction in Preventing Radiation Pneumonitis
This prospective, randomized, controlled, open-label phase II clinical study will enroll patients with thoracic malignancies who are scheduled to receive thoracic radiotherapy and whose baseline chest CT/high-resolution CT (HRCT) shows no active pulmonary disease or prior radiation-induced lung injury that could interfere with the assessment of radiation pneumonitis (RP). Eligible patients will be randomized 1:1 to a treatment group or a control group. The control group will receive standard thoracic radiotherapy and routine supportive care; the treatment group will additionally receive oral Yangyin Qingfei Formula concurrently. Patients will be followed for 12 months after radiotherapy to evaluate the formula's efficacy, safety, and potential clinical translational value in preventing RP.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Yujie Hu, MD
- Número de telefone: 18368101682
- E-mail: huyujie@zjhtcm.com
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Department of Radiotherapy, The First Affiliated Hospital of Zhejiang Chinese Medical University
-
Contato:
- chao chen, MD
- Número de telefone: 13805788140
- E-mail: 20053006@zcmu.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria
- Age 18-80 years.
- A pathologically or cytologically confirmed thoracic malignancy, including lung cancer, esophageal cancer, thymic tumors, or similar tumors.
- Planned thoracic radiotherapy, with lung tissue expected to lie within the radiation field.
- No active pulmonary disease or prior radiation-induced lung injury on baseline chest CT/HRCT that could interfere with RP assessment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Estimated survival of at least 6 months.
- Blood counts: absolute neutrophil count >=3.0 x 10^9/L, platelets >=100 x 10^9/L, and hemoglobin >=90 g/L.
- Biochemistry: total bilirubin, blood urea nitrogen, and creatinine <=1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase <=2 times the ULN.
- Ability to eat normally and take a Chinese herbal decoction; voluntary participation and written informed consent.
Exclusion criteria
- Baseline chest CT/HRCT showing active pulmonary infection, interstitial lung disease, marked pulmonary fibrosis, immunotherapy-related pneumonitis, tumor-related post-obstructive pneumonia, or another pulmonary condition that could interfere with RP assessment.
- Unequivocal tumor progression according to RECIST 1.1, or an investigator's judgment that radiotherapy and follow-up cannot be completed in the near term.
- Severe hepatic, renal, cardiovascular, gastrointestinal, or metabolic disease that could affect the safety or efficacy assessment of the study treatment.
- Pregnancy or breastfeeding, or a severe psychiatric disorder that prevents cooperation with the study.
- Participation in another interventional clinical trial within the previous 3 months.
- Regular use of other Chinese herbal medicines, Chinese patent medicines, or antifibrotic drugs specifically intended to prevent RP.
- Poor adherence, inability to take the herbal decoction regularly, or inability to complete scheduled follow-up.
- Any other condition judged by the investigator to make the patient unsuitable for enrollment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Yangyin Qingfei Formula plus standard thoracic radiotherapy and routine supportive care
|
Yangyin Qingfei decoction will contain Tai Zi Shen (Pseudostellariae Radix) 15 g, Mai Dong (Ophiopogonis Radix) 15 g, Tian Dong (Asparagi Radix) 15 g, Nan Sha Shen (Adenophorae Radix) 15 g, Bei Sha Shen (Glehniae Radix) 15 g, Huang Qin (Scutellariae Radix) 15 g, and Jiao Shan Zhi (charred Gardeniae Fructus) 9 g. One daily prescription will be administered in two doses, 200 mL per dose. If grade 1 gastrointestinal discomfort or another adverse reaction judged possibly related to the decoction occurs, the dose may be reduced to 100 mL twice daily and restored to 200 mL twice daily after symptoms resolve. For grade 2 adverse reactions, the decoction may be suspended and symptomatic treatment provided; after recovery to grade 0-1, treatment may be resumed, with or without dose reduction, at the investigator's discretion. If a grade >=3 adverse reaction, a serious adverse event, or clinically significant decoction-related intolerance occurs, decoction treatment should be stopped, with the r |
|
Comparador Ativo: Standard thoracic radiotherapy plus routine supportive care
Standard thoracic radiotherapy plus routine supportive care |
The control group will receive standard thoracic radiotherapy and routine supportive care without Yangyin Qingfei decoction. Supportive care includes nutritional support and symptomatic management, such as cough relief, expectoration, relief of wheezing, and anti-infective treatment when necessary. Chemotherapy, targeted therapy, or immunotherapy may be administered during follow-up at the investigator's discretion, under the same principles as in the treatment group. Prophylactic amifostine, nintedanib, or other antifibrotic drugs will not be used routinely, nor will other Chinese herbal medicines, Chinese patent medicines, or health supplements specifically intended to prevent RP be used. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Incidence of grade >=2 RP
Prazo: 3 months after radiotherapy completion
|
3 months after radiotherapy completion
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: chao chen, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University
Publicações e links úteis
Publicações Gerais
- Giuranno L, Ient J, De Ruysscher D, Vooijs MA. Radiation-Induced Lung Injury (RILI). Front Oncol. 2019 Sep 6;9:877. doi: 10.3389/fonc.2019.00877. eCollection 2019.
- Hou Z, Dong B, Yao Q, Chen H, Shao Q, Li M, Wang J, Chen K, Zhu Z, Peng F, Wei S, Hu X, Li J, Liu M, Xu B, Zheng S, Bi N, Zheng S, Xu Q, Chen B, Wu C, Li R, Chen W, Liu X, Tian Y, Li X, Guo S, Zhao L, Zhu Y, Cai L, Li Q, Li L, Zhang H, Hu C, Wang L, Li Q, Chen B, Chen M. Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Dec;26(12):1552-1562. doi: 10.1016/S1470-2045(25)00515-7. Epub 2025 Nov 6.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2027-KS-133-01
- 2027117845 (Número de outro subsídio/financiamento: 2027 Annual Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data will not be publicly released. Data may be available from the principal investigator upon reasonable request with a formal data-use agreement
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .